Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Windyga

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Journal of Thrombosis and Haemostasis : JTH|February 23, 2012
Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophiliaJ N Mahlangu, M J Coetzee, M Laffan, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 11, 2010
Registry of inherited bleeding disorders in Poland--current status and potential role of the HemoRec databaseJ Zdziarska, K Chojnowski, A Klukowska, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 11, 2004
Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin SDH in previously treated patients with severe haemophilia AD M Wolf, R Rokicka-Milewska, S Lopaciuk, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 5, 2014
Efficacy and safety of a recombinant factor IX (Bax326) in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open-label, uncontrolled, multicentre, phase III studyJ Windyga, T Lissitchkov, O Stasyshyn, et al.
Journal of Thrombosis and Haemostasis : JTH|September 13, 2015
Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicityJ N Mahlangu, K N Weldingh, S R Lentz, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|November 8, 2001
Factor V Leiden, prothrombin gene G20210A variant, and methylenetetrahydrofolate reductase C677T genotype in young adults with ischemic strokeS Lopaciuk, K Bykowska, H Kwiecinski, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 12, 2010
Modulation of factor VIII-specific memory B cellsB M Reipert, P Allacher, C Hausl, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 13, 2006
Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitorsJ Astermark, M Morado, A Rocino, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 29, 2017
PK-guided personalized prophylaxis with Nuwiq<sup>®</sup> (human-cl rhFVIII) in adults with severe haemophilia AT Lissitchkov, L Rusen, P Georgiev, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 11, 2007
Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitorsJ Astermark, A Rocino, M Von Depka, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Journal of Thrombosis and Haemostasis : JTH|February 23, 2012
Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophiliaJ N Mahlangu, M J Coetzee, M Laffan, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 11, 2010
Registry of inherited bleeding disorders in Poland--current status and potential role of the HemoRec databaseJ Zdziarska, K Chojnowski, A Klukowska, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 11, 2004
Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin SDH in previously treated patients with severe haemophilia AD M Wolf, R Rokicka-Milewska, S Lopaciuk, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 5, 2014
Efficacy and safety of a recombinant factor IX (Bax326) in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open-label, uncontrolled, multicentre, phase III studyJ Windyga, T Lissitchkov, O Stasyshyn, et al.
Journal of Thrombosis and Haemostasis : JTH|September 13, 2015
Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicityJ N Mahlangu, K N Weldingh, S R Lentz, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|November 8, 2001
Factor V Leiden, prothrombin gene G20210A variant, and methylenetetrahydrofolate reductase C677T genotype in young adults with ischemic strokeS Lopaciuk, K Bykowska, H Kwiecinski, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 12, 2010
Modulation of factor VIII-specific memory B cellsB M Reipert, P Allacher, C Hausl, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 13, 2006
Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitorsJ Astermark, M Morado, A Rocino, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 29, 2017
PK-guided personalized prophylaxis with Nuwiq<sup>®</sup> (human-cl rhFVIII) in adults with severe haemophilia AT Lissitchkov, L Rusen, P Georgiev, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 11, 2007
Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitorsJ Astermark, A Rocino, M Von Depka, et al.
Pageof 4